Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TTI 101

Next Previous
Drug Profile

TTI 101

Alternative Names: C-188-9; TTI-101

Latest Information Update: 05 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baylor College of Medicine
  • Developer Tvardi Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Naphthalenes; Small molecules; Sulfonamides
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HER2 negative breast cancer; Idiopathic pulmonary fibrosis; Liver cancer
  • Phase I/II Adenocarcinoma
  • Preclinical Fibrosis; Inflammation
  • No development reported Solid tumours

Most Recent Events

  • 27 May 2025 Tvardi Therapeutics completes enrolment in a phase II trial for Idiopathic pulmonary fibrosis in USA (NCT05671835)
  • 19 Mar 2025 Updated efficacy, adverse events, pharmacodynamics and pharmacokinetics data from a phase I trial in Solid tumours released by Tvardi Therapeutics
  • 21 Feb 2025 Tvardi Therapeutics terminates a phase I/II trial in Her2 negative Breast cancer (Metastatic disease, Combination therapy, Late-stage disease, Inoperable/Unresectable, Second line therapy or greater) in USA (PO) (NCT05384119)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top